Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 17;7(7):CD006932.
doi: 10.1002/14651858.CD006932.pub4.

Pharmacological treatment of depression in people with a primary brain tumour

Zachary Beevers  1 , Sana Hussain  1 , Florien W Boele  2 , Alasdair G Rooney  3
Affiliations

Pharmacological treatment of depression in people with a primary brain tumour

Zachary Beevers et al. Cochrane Database Syst Rev. .

Abstract

Background: This is the second updated version of the Cochrane Review published in Issue 3, 2010 and first updated in Issue 5, 2013. People with a primary brain tumour often experience depression, for which drug treatment may be prescribed. However, they are also at high risk of epileptic seizures, cognitive impairment, and fatigue, all of which are potential adverse side effects of antidepressants. The benefit, or harm, of pharmacological treatment of depression in people with a primary brain tumour is unclear.

Objectives: To assess the benefits and harms of pharmacological treatment of depression in people with a primary brain tumour.

Search methods: We updated the search to include CENTRAL, MEDLINE, Embase, and PsycINFO to September 2019. As in the original review, we also handsearched Neuro-Oncology, Journal of Neuro-Oncology, Journal of Neurology, Neurosurgery and Psychiatry, and Journal of Clinical Oncology: for the current update we handsearched the latest three years of articles from these journals (up to November 2019).

Selection criteria: We searched for all randomised controlled trials (RCTs), controlled clinical trials, cohort studies, and case-control studies of any pharmacological treatment of depression in people with a histologically diagnosed primary brain tumour.

Data collection and analysis: No studies met the inclusion criteria.

Main results: We found no eligible studies evaluating the benefits of any pharmacological treatment of depression in people with a primary brain tumour.

Authors' conclusions: We identified no high-quality studies that investigated the value of pharmacological treatment of depression in people with a primary brain tumour. RCTs and detailed prospective studies are required to inform the effective pharmacological treatment of this common and important complication of brain tumours. Since the last version of this review none of the related new literature has provided additional information to change these conclusions.

PubMed Disclaimer

Conflict of interest statement

Zachary Beevers: none known Sana Hussain: none known Florien W Boele: none known Alasdair G Rooney: none known

Figures

1
1
PRISMA study flow diagram.
See this image and copyright information in PMC

Update of

References

References to studies excluded from this review

Attia 2012 {published data only}
    1. Attia A, Rapp S, Case L, D'Agostino R, Lesser G, Naughton M, et al. Phase II study of ginkgo biloba in irradiated brain tumour patients: effect on cognitive function, quality of life, and mood. Journal of Neuro-Oncology 2012;109(2):357-63. [PMID: ] - PMC - PubMed
Blackhall 2009 {published data only}
    1. Blackhall K, Petronic G, Shu J, Baum L, Farace E. A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. Journal of Palliative Medicine 2009;12(5):433-9. [PMID: ] - PubMed
Boele 2013 {published data only}
    1. Boele F, Duow L, Groot M, Thuijl H, Cleijne W, Heimans J, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Journal of Neuro-Oncology 2013;15(10):1420-8. [PMID: ] - PMC - PubMed
Caudill 2011 {published data only}
    1. Caudill JS, Brown PD, Cerhan JH, Rummans TA. Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival. The Mayo Clinic experience. American Journal of Clinical Oncology 2011;34:385-7. - PubMed
Gehring 2012 {published data only}
    1. Gehring K, Patwardhan S, Collins R, Groves M, Etzel C, Meyers A, et al. A randomized trial of the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumour. Journal of Neuro-Oncology 2012;107(1):165-74. [PMID: ] - PubMed
Gothelf 2005 {published data only}
    1. Gothelf D, Rubinstein M, Shemesh E, Miller O, Farbstein I, Klein A, et al. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer. Journal of the American Academy of Child and Adolescent Psychiatry 2005;44(12):1258-62. [PMID: ] - PubMed
Knudsen‐Baas 2018 {published data only}
    1. Knudsen-Baas K, Johannesen T, Myklebust T, Aarseth J, Owe J, Gilhus E, et al. Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV. Journal of Neuro-Oncology 2018;140(3):739-48. [PMID: ] - PubMed
Koval'chuk 2007 {published data only}
    1. Koval'chuk VV. Pharmacologic correction of psycho-emotive disorders in the rehabilitation of patients after removal of brain tumors. Voprosy Onkologii 2007;53(6):704-10. - PubMed
Litofsky 2004 {published data only}
    1. Litofsky NS, Farace E, Anderson F Jr. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 2004;54(2):358-66. - PubMed
Maschio 2013 {published data only}
    1. Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, et al. Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. Epileptic Disorders 2013;14:388-97. [PMID: ] - PubMed
Meyers 1998 {published data only}
    1. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. Journal of Clinical Oncology 1998;16(7):2522-7. - PubMed
Morrow 2003 {published data only}
    1. Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PLR, Flynn PJ. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology 2003;21(24):4635-41. - PubMed
Moss 2006 {published data only}
    1. Moss EL, Simpson JSA, Pelletier G, Forsyth P. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psycho-Oncology 2006;15:259-67. - PubMed
Oyewumi 1981 {published data only}
    1. Oyewumi LK, Lapierre YD. Efficacy of lithium in treating mood disorder occurring after brain stem injury. American Journal of Psychiatry 1981;138(1):110-2. - PubMed
Rabey 1985 {published data only}
    1. Rabey JM, Avrahami E. Unmasking of cerebellar tumours by amitriptyline in depressive patients. Journal of Neurology, Neurosurgery and Psychiatry 1985;48(3):291. - PMC - PubMed
Shaw 2006 {published data only}
    1. Shaw EG, Rosdhal R, D'Agostino RB Jr, Lovato J, Naughton MJ, Robbins ME, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. Journal of Clinical Oncology 2006;24(9):1415-20. - PubMed
Walker 2010 {published data only}
    1. Walker A, Grainge M, Bates T, Card T. Survival of glioma and colorectal cancer patients using tricyclic antidepressants post-diagnosis. Cancer Causes & Control 2012;23(12):1959-64. [PMID: ] - PubMed
Wellisch 2006 {published data only}
    1. Wellisch DK, Steh B, Kaleita TA, Graham CA, Cloughes TF. A modafinil therapeutic trial for adult brain tumor patients: III. Depression outcomes. Psycho-Oncology 2006;15 Suppl:455.
Wirz 2010 {published data only}
    1. Wirz S, Nadstawek J, Kuhn J, Vater S, Junker U, Wartenberg H. Modafinil for the treatment of cancer-related fatigue: an intervention study [Modafinil zur behandlung der tumorfatigue]. Schmerz 2010;24:587-95. [PMID: ] - PubMed

References to ongoing studies

Zhou 2018 {published and unpublished data}
    1. Zhou Y, Peng Y, Fang J, Sun W, Zhang G, Zhen L, et al. Effect of low-dose ketamine on PerioperAtive depreSsive Symptoms in patients undergoing Intracranial tumOr resectioN (PASSION): study protocol for randomized controlled trial. Trials 2018;19:463. - PMC - PubMed

Additional references

Aaronson 1993
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 1993;85(5):365-76. - PubMed
APA 2016
    1. American Psychiatric Association. User's Guide for the Structured Clinical Interview for DSM-5 Disorders - Clinical Version (SCID-5-CV). Washington, DC: American Psychiatric Association, 2016.
Baltenberger 2014
    1. Baltenberger E, Schmitt G, Thomas C. Treatment of depressive symptoms in patients with cancer. Mental Health Clinician 2014;4(3):114-7.
Beck 1996
    1. Beck AT, Brown G, Steer R. Beck Depression Inventory-II. Pearson, 1996.
Cassano 2004
    1. Cassano P, Fava M. Tolerability issues during long-term treatment with antidepressants. Annals of Clinical Psychiatry 2004;16(1):15-25. - PubMed
Claus 2015
    1. Claus E, Walsh K, Wiencke J, Molinaro A, Wiermels J, Schildkraut, et al. Survival and low grade glioma: the emergence of genetic information. Neurosurgery Focus 2015;38(1):E6. - PMC - PubMed
Dalton 2009
    1. Dalton SO, Laursen TM, Ross L, Mortensen PB, Johansen C. Risk for hospitalisation with depression after a cancer diagnosis: a nationwide, population-based study of cancer patients in Denmark from 1973 to 2003. Journal of Clinical Oncology 2009;27:1440-5. - PubMed
de Robles 2015
    1. Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St Germaine-Smith C. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro-Oncology 2015;17(6):776-83. - PMC - PubMed
Feuerstein 2007
    1. Feuerstein M, Hansen JA, Calvio LC, Johnson L, Ronquillo JG. Work productivity in brain tumor survivors. Journal of Occupational and Environmental Medicine 2007;49:803-11. - PubMed
Gathinji 2009
    1. Gathinji M, McGirt M, Attenello F, Chaichana K, Than K, Olivi A, et al. Association of preoperative depression and survival after resection of malignant brain astrocytoma. Surgical Neurology 2009;71(3):299-303. - PubMed
Gazzotti 2011
    1. Gazzotti M, Malheiros S, Alith M, Nascimento O, Santoro I, Jardim J, et al. Quality of life and physical limitation in primary brain tumour patients. Quality of Life Research 2011;20(10):1639-43. - PubMed
Gelder 2012
    1. Gelder M, Andreasen N, Lopez-Ibor J, Geddes J. Oxford Textbook of Psychiatry. 2nd edition. Oxford: Oxford University Press, 2012.
Hachad 2002
    1. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Therapeutic Drug Monitoring 2002;24(1):91-103. - PubMed
Hackett 2008
    1. Hackett ML, Anderson CS, House AO, Xia J. Interventions for treating depression after stroke. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003437.pub3] - DOI - PubMed
Hesdorffer 2000
    1. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in older adults. Annals of Neurology 2000;47:246-9. - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hill 2015
    1. Hill T, Coupland C, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. BMC Psychiatry 2015;15:315. - PMC - PubMed
Huang 2017
    1. Huang J, Zeng C, Xiao J, Zhao D, Tang H, Wu H, et al. Association between depression and brain tumour: a systematic review and meta-analysis. Oncotarget 2017;8(55):94932-43. - PMC - PubMed
Iosifescu 2004
    1. Iosifescu DV, Bankier B, Fava M. Impact of medical co-morbid disease on antidepressant treatment of major depressive disorder. Current Psychiatry Reports 2004;6(3):193-201. - PubMed
Lapointe 2018
    1. Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet 2018;392(10145):432-46. - PubMed
Lima 2005
    1. Lima MS, Moncrieff J, Soares BGO. Drugs versus placebo for dysthymia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001130] - DOI - PubMed
Litofsky 2009
    1. Litofsky NS, Resnick AG. The relationship between depression and brain tumours. Journal of Neuro-Oncology 2009;94(2):153-61. - PubMed
Louis 2016
    1. Louis DN, Perry A, Reifenberger G, Deimling A, Figaraella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathalogica 2016;131:803-20. - PubMed
Mainio 2005
    1. Mainio A, Hakko H, Timonen M, Niemelä A, Koivukangas J, Räsänen P. Depression in relation to survival among neurosurgical patients with a primary brain tumor: a 5-year follow-up study. Neurosurgery 2005;56:1234-42. - PubMed
Mainio 2006a
    1. Mainio A, Hakko H, Niemela A. Gender difference in relation to depression and quality of life among patients with a primary brain tumour. European Psychiatry: The journal of the European Psychiatric Association 2006;21(3):194-9. - PubMed
Mainio 2006b
    1. Mainio A, Tuunanen S, Hakko H. Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. European Archives of Psychiatry and Clinical Neuroscience 2006;256(8):516-21. - PubMed
McHorney 1993
    1. McHorney CA, Ware JE, Raczek AE. The MOS 3-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care 1993;31(3):247-63. - PubMed
Mendoza 1999
    1. Mendoza T, Wang S, Cleeland C, Morrissey M, Johnson B, Wendt J, et al. The rapid assessment of fatigue severity in cancer patients. Cancer 1999;85(5):1186-96. - PubMed
Moncrieff 2004
    1. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003012.pub2] - DOI - PMC - PubMed
Montgomery 2005
    1. Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. International Journal of Clinical Practice 2005;59(12):1435-40. - PubMed
Mottram 2006
    1. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD003491.pub2] - DOI - PMC - PubMed
Mula 2017
    1. Mula M. Depression in epilepsy. Current Opinion in Neurology 2017;30(2):180-6. - PubMed
NICE 2009
    1. NICE. Depression in adults with a chronic physical health problem: the NICE guideline on treatment and management: National Clinical Practice Guideline 91 NICE. www.nice.org.uk/guidance/cg91 (accessed prior to 29 June 2020) 2009.
Pallud 2019
    1. Pallud J, McKhann G. Diffuse low-grade glioma related epilepsy. Neurosurgery Clinics of North America 2019;30(1):43-54. - PubMed
Pangilinan 2007
    1. Pangilinan PH Jr, Kelly BM, Pangilinan JM. Depression in the patient with brain cancer. Community Oncology 2007;4:533-7.
Patel 2019
    1. Patel AP, Fisher JL, Nichols E, Feigin VL, Murray CJL, Fitzmaurice C, et al. Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology 2019;18(4):376-93. - PMC - PubMed
Peretti 2000
    1. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin re-uptake inhibitors (Antidepressant selection: Proceedings from a TCA/SSRI consensus conference). Acta Psychiatrica Scandinavia 2000;101 Suppl 403:17-25. - PubMed
Price 2008
    1. Price TRP, Goetz KL, Lovell MR. Neuropsychiatric aspects of brain tumors. In: Yudofsky SC, Hales RE, editors(s). The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioural Neurosciences. 5th edition. Arlington (VA): American Psychiatric Publishing Inc, 2008.
Radloff 1977
    1. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1977;1(3):385-401.
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rihmer 2007
    1. Rihmer Z. Suicide risk in mood disorders. Current Opinion in Psychiatry 2007;20:17-22. - PubMed
Rock 2014
    1. Rock P, Roiser J, Riedel W, Blackwell A. Cognitive impairment in depression: a systematic review and meta-analysis. Psychological Medicine 2014;44(10):2029-40. - PubMed
Rooney 2011
    1. Rooney AG, McNamara S, MacKinnon M, Fraser M, Rampling R, Carson A, et al. Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. Journal of Clinical Oncology 2011;29:4307-12. - PubMed
Ruda 2010
    1. Ruda R, Trevisan E, Soffietti R. Epilepsy and brain tumours. Current Opinion in Oncology 2010;22(6):611-20. - PubMed
Sayyah 2016
    1. Sayyah M, Eslami K, AlaiShehni S, Kouti L. Cognitive function before and during treatment with selective serotonin reuptake inhibitors in patients with depression or obsessive-compulsive disorder. Psychiatry Journal 2016 Aug 15 [Epub ahead of print]. [DOI: 10.1155/2016/5480391] [PMCID: PMC5002481] - DOI - PMC - PubMed
Sharpe 2004
    1. Sharpe M, Strong V, Allen K. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. British Journal of Cancer 2004;90:314-20. - PMC - PubMed
Spina 2016
    1. Spina E, Pisani F, deLeon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacological Research 2016;106:72-86. - PubMed
Stein 2004
    1. Stein K, Jacobsten P, Blanchard C, Thors C. Further validation of the Multidimensional Fatigue Symptom Inventory-Short Form. Journal of Pain Symptom Management 2004;27(1):14-23. - PMC - PubMed
Stupp 2009
    1. Stupp R, Hegi ME, Mason WP, den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology 2009;10(5):459-66. - PubMed
Weitzner 1995
    1. Weitzner MA, Myers C, Gelke C, Byrne K, Levin C, Cella D. The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995;75(5):1151–61. - PubMed
Weitzner 1999
    1. Weitzner MA. Psychosocial and neuropsychiatric aspects of patients with primary brain tumors. Cancer Investigation 1999;17(4):285-91. - PubMed
Wen 2008
    1. Wen PY, Kesari S. Malignant gliomas in adults. New England Journal of Medicine 2008;359:492-507. - PubMed
Wiemels 2010
    1. Wiemels J, Wrensch M, Claus E. Epidemiology and etiology of meningioma. Journal of Neuro-Oncology 2010;99(3):307-14. - PMC - PubMed
Wijkstra 2005
    1. Wijkstra J, Lijmer J, Balk F, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004044.pub2] - DOI - PubMed
Yellen 1997
    1. Yellen S, Cella D, Webster K, Blendowksi C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain Symptom Management 1997;13(2):63-74. - PubMed
Zigmond 1983
    1. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavia 1983;67(6):361-70. - PubMed

References to other published versions of this review

Rooney 2010
    1. Rooney A, Grant R. Pharmacological treatment of depression in patients with a primary brain tumour. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD006932.pub2] - DOI - PubMed
Rooney 2013
    1. Rooney AG, Grant R. Pharmacological treatment of depression in patients with a primary brain tumour. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD006932.pub3] - DOI - PMC - PubMed

Publication types

MeSH terms

Substances